· AIM:Tocomparetheeffectofanti-vascularendothelial growthfactor(VEGF)monotherapyversusphotodynamic therapy (PDT)andanti-VEGFcombinationtreatmentin age-relatedmaculardegeneration(AMD). 
INTRODUCTION
A ge-relatedmaculardegeneration(AMD)isoneofthe leadingcausesofblindnessinelderlyindividualsin developedcountries [1] [2] .AMDaffectsmorethan1.75million individualsintheUnitedStates.Asaresultoftherapid agingoftheUSpopulation,thisnumberwillincreaseto approximately3millionindividualsby2020 [3] .AMDisalso aregularophthalmicdiseaseinelderlyindividualsinAsia [4] . . Vascularendothelialgrowthfactor(VEGF),apotent angiogenicmolecule,playsanimportantroleinthe developmentofCNVinnAMD [6] inthetissue microenvironment.Treatmentsusinganti-VEGF monotherapyhavebeenestablishedasthestandardtherapy forCNVandAMD.Inthesecases,patientsrequiremultiple treatments [7] toslowdownthegrowthofnewabnormalblood vessels.Photodynamictherapy(PDT)isanothertreatment approachforAMDpatients.Itincludesintravenousinjection ofverteporfin,aphotosensitizingdrug,whichinjuresnewly formedCNVandthusreducestheriskofvisionlossand retardsdiseaseprogressioninpatientswithAMD.Its efficacyandsafetyinnAMDhavebeendemonstratedby severalstudies [8] [9] [10] . Itwashypothesizedthatthecombinationofthesetwo treatmentsmayhaveasynergisticeffectonimprovingvisual acuity(VA)andreducingthecenterretinalthickness(CRT), theCNVandthenumberofanti-VEGFtreatments [5, 11] . Currently,there isnoconsensusregardingwhether combinationtherapyismoreeffectivecomparedwith anti-VEGFmonotherapy.Weperformedacomprehensive, computerized,onlinesearchoftherandomizedcontrolled trialsthathavecomparedanti-VEGFmonotherapyversus PDTandanti-VEGFcombinationtreatmentinAMD.Using allavailabledata,asystematicreviewandMeta-analysisof thecomparisonofthetwotherapieswasperformedto estimate theefficacyofanti-VEGFmonotherapyand combinationtherapy. METHODS LiteratureSearch WesearchedPubMed,WebofScience andtheCochraneLibraryusingthefollowingsearchterms: ("age relatedmaculardegeneration''OR''AMD''OR "maculardegeneration")and(''PDT''OR''photodynamic therapy''OR"visudyne")and(''anti-VEGF''OR''vascular endothelialgrowthfactors''OR"endothelialgrowthfactors" OR"angiogenesisinhibitors"OR"angiogenesisinducing agents")andotheralternativenames("macugen"OR "pegaptanib"OR"lucentis"OR"rhufab"OR"ranibizumab" OR"bevacizumab"OR"avastin" [12] [13] [14] [15] [16] [17] [18] [19] .Thefollow-uptimes inallstudiescomprised12mo.Insomecases,rawdatawere kindlyprovidedbytheauthor [13] ,andsomewereprocured fromNovartis'dataonfile [15, 17] . 
